Market news

Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy. Launches Caspian Therapeutics With $50 Million Financing Kura said it is launching Caspian Therapeutics alongside a $50 million financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Co. (NYSE:LLY), Kura Oncology, members of Kura’s leadership team, and other investors. The stated goal is to advance the company’s work in meni

Detailed price information for Kura Oncology (KURA-Q) from The Globe and Mail including charting and trades.

– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral pres

Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. Ms. Fulk will join Kura’s senior leade

SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on September 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 48,450 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option

Kura Oncology stock has delivered a solid 55.5% return over the past year, yet on broad valuation checks it still screens as expensive rather than a clear bargain. For investors, that combination of strong recent gains and a low value score raises questions about how much good news is already reflected in the current share price. The 55.5% 1 year gain highlights how strongly sentiment has improved toward Kura Oncology, which can leave less room for disappointment if expectations...

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceSeptember 8, 20263:45 p.m. ET / 12:45 p.m. PT Cantor Global Healthcare ConferenceSeptember 9, 20269:10 a.m. ET / 6:10 a.m. PT Morgan Stanley Global Healthcare Conference September 16, 20267:45 a.m. ET / 4:45 a.m.

Detailed price information for Kura Oncology (KURA-Q) from The Globe and Mail including charting and trades.

Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.

Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.

Kura Oncology stays a “strong buy” on KOMZIFTI FDA approval, early revenue growth, and AML trial catalysts. Click here to read my latest analysis.

According to a filing with the SEC, Kura President and CEO Troy Edward Wilson bought 100,000 shares of common stock on August 24 for about $1.24 million in total.

Kura Oncology stock rallies as the CEO revealed another $1.24 million purchase of company shares. Wall Street continues to see massive further upside in KURA shares.

Wilson's purchase increases his total equity stake by 9% following a 62% one-year stock return, signaling confidence in the oncology biotech's pipeline.

These are the stocks posting the largest moves midday.

Kura Oncology Inc. (NASDAQ:KURA) shares climbed 11.

These are the stocks posting the largest moves in early trading.

Detailed price information for Kura Oncology (KURA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Kura Oncology (KURA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Kura Oncology (KURA-Q) from The Globe and Mail including charting and trades.

The mean of analysts' price targets for Kura Oncology (KURA) points to a 178.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Kura Oncology recently reported past second-quarter 2026 results, with revenue rising to US$20.87 million while net loss widened to US$68.33 million, alongside the publication in Blood of extensive preclinical data on its FDA-approved menin inhibitor ziftomenib (KOMZIFTI) for relapsed or refractory NPM1-mutated AML. The Blood manuscript highlights ziftomenib’s differentiated binding profile, activity across genetically defined leukemia models, and retained activity against certain...

According to a filing with the Securities and Exchange Commission, President and CEO Wilson bought 100,000 shares at an average price of $11.12.

Detailed price information for Kura Oncology (KURA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Inovio Pharma (INO-Q) from The Globe and Mail including charting and trades.

Moby summary of Kura Oncology, Inc.'s Q2 2026 earnings call

Kura Oncology (KURA) delivered earnings and revenue surprises of +13.48% and +23.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

– KOMZIFTI® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI® achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class, establishing leadership after just two full quarters of launch – – Long-term, frontline AML data presented at EHA 2026 support potential for ziftomenib to transform standard of care and a $7 billion TAM – – Clinical updates support darlifarnib’s potentia